Company: SXTPW
Filing Date: 2025-08-27
Form Type: DEF 14A
Source: 0001213900-25-080878
Chunk: 24

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-27
Form: DEF 14A
Chunk 24
---
 waivers of its
requirements, on our website or in filings under the Exchange Act to the extent required by applicable rules and exchange requirements.

Board Leadership

The Nominating and Corporate Governance Committee
annually reviews the Board’s leadership structure and evaluates the performance and effectiveness of the Board. The Board retains
the authority to modify its leadership structure in order to stay current with our Company’s circumstances and advance the best
interests of the Company and its stockholders as and when appropriate. The Board’s annual self-evaluation includes questions regarding
the Board’s opportunities for open communication and the effectiveness of executive sessions.

Corporate Governance Policies and Practices

.

The Board undertakes an annual review of director
independence. During this review, the Board considers transactions and relationships between each director or any member of his or her
immediate family and the Company and its subsidiaries and affiliates. The purpose of this review is to determine whether any such relationships
or transactions were inconsistent with a determination that the director is independent. As a result of this review, the Board affirmatively
determined that three (3) of the five (5) of the directors are independent of the Company and its management under Nasdaq rules. Geoffrey
Dow and Cheryl Xu are not considered independent because of their employment by the Company.

<div align='center'>12</div>

In determining that the other directors did not
have a material relationship with the Company, the Board concluded that Messrs. Allen, Toovey and Field had no other relationship with
the Company other than their relationship as a director.

. The Audit Committee,
the Compensation Committee and the Nominating and Corporate Governance Committee of the Board operate pursuant to written charters. These
charters were approved by the Board and reflect certain best practices in corporate governance. These charters comply with the requirements
of the Nasdaq. Each charter is available on the Company’s website at: https://investors.60degreespharma.com/corporate-governance/governance-overview.

. Our non-management
directors meet in executive session at each regular Board meeting. The executive sessions are attended only by the non-management directors.
Our independent directors meet in executive sessions at least once per year and met once in 2024.

. Information and data
important to the directors’ understanding of the business or matters to be considered at a Board or Board committee meeting are,
to the extent practical, distributed to the directors sufficiently in advance of the meeting to allow careful review prior to the meeting.

. The Board